Best Peptides for Fat Loss: Semaglutide, Tirzepatide, Retatrutide, Adipotide, and Tesofensine
The pharmacological landscape for fat loss has been transformed over the past decade by incretin-based peptide therapies. This article covers five of the most researched compounds — from FDA-approved weekly injectables to preclinical candidates with novel mechanisms — with an honest account of the clinical data, mechanisms, and research status of each.
Research & Educational Content. Some compounds in this article are FDA-approved medications that require a prescription. Others are research-phase or preclinical compounds not approved for human use. This article is for educational purposes only. Consult a licensed healthcare provider before using any medication or research compound.
Quick Comparison
| Compound | Mechanism | Status | Weight Loss | Route |
|---|---|---|---|---|
| Semaglutide | GLP-1 agonist | FDA-Approved | ~15% (STEP 1) | Weekly injection |
| Tirzepatide | GLP-1 + GIP dual | FDA-Approved | ~21% (SURMOUNT-1) | Weekly injection |
| Retatrutide | GLP-1 + GIP + Glucagon | Phase 3 | ~24% (Phase 2) | Weekly injection |
| Adipotide | Fat vasculature apoptosis | Preclinical | ~11% BW (primates) | Daily injection |
| Tesofensine | Triple monoamine reuptake inhibitor | Phase 3 / Not approved | ~13% (Phase 2) | Oral daily |
Weight loss figures reflect mean results from primary RCTs or largest preclinical study at highest studied dose. Not directly comparable across compounds due to different trial designs, populations, and durations.
Semaglutide
GLP-1 Receptor Agonist
Mechanism of Action
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone secreted from the intestinal L-cells in response to food intake. It acts on the brain's hypothalamus and brainstem to suppress appetite, slows gastric emptying (increasing satiety), and enhances glucose-dependent insulin secretion. Semaglutide's half-life of approximately 7 days — achieved through fatty acid modification and albumin binding — allows once-weekly subcutaneous dosing. This is the mechanism behind both its glycemic control in diabetes (Ozempic) and significant weight reduction in obesity (Wegovy).
Research & Clinical Data
The STEP trial program (Semaglutide Treatment Effect in People with Obesity) established semaglutide 2.4 mg weekly as one of the most effective pharmacological weight loss interventions ever studied in large-scale RCTs. STEP 1 demonstrated an average 14.9% body weight reduction versus 2.4% in placebo over 68 weeks. STEP 5 extended this to 104 weeks with sustained efficacy. These are landmark results — no prior non-surgical intervention had achieved this magnitude of reproducible weight loss in controlled trials.
Dosing Protocol
0.25 mg weekly (starting dose) → titrated to 2.4 mg weekly over 16–20 weeks
Route
Subcutaneous injection, once weekly
Titration is mandatory — skipping escalation dramatically increases GI side effects
Nausea, vomiting, and constipation are the most common adverse effects, typically dose-dependent
Weight regain occurs after discontinuation — not a permanent metabolic reset
Requires cold storage (36–46°F); does not need reconstitution — comes pre-formulated
Tirzepatide
GLP-1 / GIP Dual Receptor Agonist
Mechanism of Action
Tirzepatide is the first approved dual agonist — simultaneously activating both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is another incretin hormone that works synergistically with GLP-1 to reduce appetite and increase energy expenditure. The dual mechanism appears to produce additive or synergistic fat loss beyond GLP-1 alone. Like semaglutide, tirzepatide is fatty acid-modified for extended half-life (~5 days) enabling once-weekly dosing.
Research & Clinical Data
The SURMOUNT trial program established tirzepatide as the most effective approved weight loss pharmacotherapy to date. SURMOUNT-1 showed a mean 20.9% body weight reduction at the 15 mg dose over 72 weeks versus 3.1% placebo — the highest reduction ever documented in an RCT of this scale for a non-surgical intervention. Approximately 57% of participants at the highest dose achieved ≥20% weight loss. Head-to-head comparisons with semaglutide (SURPASS-6) consistently show tirzepatide produces greater HbA1c and weight reduction.
Dosing Protocol
2.5 mg weekly (starting dose) → titrated to 5, 10, or 15 mg weekly
Route
Subcutaneous injection, once weekly
Currently demonstrates the highest efficacy among approved pharmacological weight loss agents
GI side effects profile similar to semaglutide — titration essential
Also approved for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound)
Emerging data suggests favorable cardiovascular and metabolic outcomes beyond weight loss
Retatrutide
GLP-1 / GIP / Glucagon Triple Receptor Agonist
Mechanism of Action
Retatrutide is the first triple receptor agonist in advanced clinical development — simultaneously activating GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor agonism is the key differentiator: glucagon increases energy expenditure (thermogenesis) and directly stimulates lipolysis in adipose tissue. This third mechanism targets fat burning through a different pathway than the satiety-focused GLP-1/GIP dual action, providing a theoretical basis for the remarkable weight loss figures seen in early trials. The compound has a long half-life (~6 days) enabling once-weekly dosing.
Research & Clinical Data
Phase 2 trial data published in the New England Journal of Medicine (2023) showed a mean body weight reduction of 24.2% at the highest dose (12 mg) over 48 weeks — exceeding the efficacy observed with both semaglutide and tirzepatide at comparable timepoints. Phase 3 trials are currently enrolling. If Phase 3 results confirm Phase 2 findings, retatrutide could represent the most effective non-surgical weight loss intervention ever approved.
Dosing Protocol
0.5 mg weekly (starting dose) → titrated to 4, 8, or 12 mg weekly (Phase 2 protocol)
Route
Subcutaneous injection, once weekly
Not yet approved — Phase 2 data only; Phase 3 ongoing
Phase 2 GI adverse event profile consistent with GLP-1 class (nausea, vomiting, diarrhea)
Glucagon agonism adds direct lipolytic and thermogenic mechanisms absent in semaglutide/tirzepatide
24.2% mean weight reduction in Phase 2 exceeds any previously published pharmacological trial result
Research Grade Source
Third-party verified purity
Adipotide
Proapoptotic Peptide (PROHIBITIN-targeting)
Mechanism of Action
Adipotide (also known as CKGGRAKDC-GG-D(KLAKLAK)₂) works through a mechanism entirely different from GLP-1 class peptides. It is a chimeric peptide that selectively targets blood vessels feeding white adipose tissue by binding to prohibitin — a protein highly expressed on the surface of adipose vasculature. Once bound, the proapoptotic domain (D(KLAKLAK)₂) induces mitochondrial disruption and cell death specifically in the endothelial cells supplying fat depots. This selectively starves adipose tissue of its blood supply, causing fat cell death through ischemia — a fundamentally different approach from appetite suppression.
Research & Clinical Data
Proof-of-concept studies in obese rhesus monkeys (Kolonin et al., Science Translational Medicine, 2011) demonstrated significant and rapid fat loss with adipotide — approximately 11% body weight reduction over 28 days with a corresponding 27% reduction in BMI. The mechanism was confirmed histologically. However, the same study noted significant nephrotoxicity (kidney damage) in treated monkeys, including tubular vacuolization — a serious safety concern that has limited human clinical development. No human trials have been completed. The compound remains a research-stage compound with a compelling mechanism but unresolved toxicity questions.
Dosing Protocol
Animal studies: 75 mcg/kg/day subcutaneous (primate model)
Route
Subcutaneous injection
Mechanism is fundamentally different from GLP-1 class — acts on fat vasculature, not appetite
Significant nephrotoxicity observed in primate studies — this is a serious unresolved concern
No human clinical trials completed
Among the most mechanistically unique fat-loss compounds in preclinical research
Primate data showed rapid fat loss at doses that also caused kidney damage — the therapeutic window is unclear
Research Grade Source
Third-party verified purity
Tesofensine
Triple Monoamine Reuptake Inhibitor
Mechanism of Action
Tesofensine is technically not a peptide — it is a small molecule that inhibits the reuptake of serotonin, dopamine, and norepinephrine (a triple monoamine reuptake inhibitor, similar in class to sibutramine). It reduces appetite through central nervous system mechanisms, increasing satiety signaling and reducing food intake. It also increases energy expenditure through sympathomimetic activity. Originally developed as a treatment for Alzheimer's and Parkinson's disease, weight loss was identified as a significant side effect during trials, prompting development for obesity treatment.
Research & Clinical Data
A Phase 2b double-blind RCT published in The Lancet (2008) showed tesofensine 0.5 mg daily produced a mean 12.8% body weight reduction over 24 weeks — significantly greater than placebo. These results were among the largest seen for an oral anti-obesity agent at the time. Phase 3 trials were subsequently initiated but have not resulted in regulatory approval in the US or EU. Development has continued in some markets, with ongoing trials as of 2024–2025.
Dosing Protocol
0.25–0.5 mg once daily orally
Route
Oral (capsule)
Not a peptide — included here as a mechanistically distinct fat loss research compound
Cardiovascular effects (increased heart rate, blood pressure) are a noted concern at higher doses
Similar mechanism to sibutramine, which was withdrawn from markets due to cardiovascular risk
Phase 2 results are compelling — Phase 3 has not produced regulatory approval to date
Oral delivery is an advantage over injectable GLP-1 class drugs for compliance
How These Compounds Compare in Context
For maximum clinical efficacy (approved agents)
Tirzepatide currently demonstrates the highest mean weight loss of any approved pharmacological intervention (~21%), followed by semaglutide (~15%). Both have large-scale RCT safety data. If efficacy is the priority among approved drugs, tirzepatide leads.
For the most mechanistically novel pipeline compound
Retatrutide's triple receptor agonism — adding glucagon receptor activation to the GLP-1/GIP dual mechanism — produced Phase 2 results (~24%) exceeding both approved agents. It's the most closely watched compound in metabolic drug development as of 2026.
For a fundamentally different fat-targeting mechanism
Adipotide targets fat vasculature directly rather than modulating appetite or energy expenditure — a structurally distinct approach. Its primate data is compelling, but unresolved nephrotoxicity means it remains preclinical. Not appropriate for research use outside controlled study settings given the safety profile.
For oral delivery research
Tesofensine offers oral administration — a practical advantage over weekly injectables. Phase 2 efficacy was meaningful (~13%). The cardiovascular risk profile (similar to sibutramine) and the lack of Phase 3 approval are significant limitations. Oral semaglutide (Rybelsus) is now an approved alternative in the GLP-1 class for diabetes.
A Note on Weight Regain
Clinical trial data consistently shows that weight loss from GLP-1 class agents is largely reversed upon discontinuation. The STEP 4 trial (semaglutide) documented ~12% weight regain within one year of stopping treatment. This is not a failure of the drug — it reflects the chronic nature of obesity as a condition. These are treatments, not cures. Long-term management strategies should account for this biology.
Related Articles
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →